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Cell migration underlies metastatic dissemination of
cancer cells, and fast ‘‘amoeboid’’ migration in the
invasive fronts of tumors is controlled by high levels
of actomyosin contractility. Howamoeboidmigration
is regulated by extracellular signals and sustained
over time by transcriptional changes is not fully un-
derstood. Transforming growth factor b (TGF-b) is
well known to promote epithelial-to-mesenchymal
transition (EMT) and contribute to metastasis, but
melanocytes are neural crest derivatives that have
undergone EMT during embryonic development.
Surprisingly, we find that in melanoma, TGF-b pro-
motes amoeboid features such as cell rounding,
membrane blebbing, high levels of contractility, and
increased invasion. Using genome-wide transcrip-
tomics, we find that amoeboid melanoma cells are
enriched in a TGF-b-driven signature. We observe
that downstream of TGF-b, SMAD2 and its adaptor
CITED1 control amoeboid behavior by regulating
the expression of key genes that activate contractile
forces. Moreover, CITED1 is highly upregulated dur-
ingmelanoma progression, and its high expression is
associated with poor prognosis. CITED1 is coupled
to a contractile-rounded, amoeboid phenotype in a
panel of 16 melanoma cell lines, in mouse melanoma
xenografts, and in 47 human melanoma patients. Its
expression is also enriched in the invasive fronts
of lesions. Functionally, we show how the TGF-
b-SMAD2-CITED1 axis promotes different steps
associated with progression: melanoma detachment
from keratinocytes, 2D and 3Dmigration, attachment
to endothelial cells, and in vivo lung metastatic initial
colonization and outgrowth. We propose a novelCurrent Biomechanism by which TGF-b-induced transcription
sustains actomyosin force in melanoma cells and
thereby promotes melanoma progression indepen-
dently of EMT.
INTRODUCTION
The transforming growth factor b (TGF-b) signaling pathway
plays a major role in the regulation of the epithelial-to-mesen-
chymal transition (EMT), which governs morphogenesis and
the progression of carcinomas [1]. TGF-b signaling acts as a
tumor promoter in advanced epithelial tumors and drives metas-
tasis [2] by favoring EMT, proliferation, dissemination, angiogen-
esis, and tumor escape from immune surveillance [3–5]. TGF-b
ligands bind to the type II TGF-b receptor, in turn, activating
the type I receptor. The type I receptor phosphorylates down-
stream effectors SMAD2 and SMAD3, which then associate
with SMAD4 [6, 7]. The SMAD2/3-SMAD4 complex accumulates
in the cell nucleus, where it regulates the transcription of various
target genes.
SMAD-mediated transcription is fine-tuned by a variety of co-
factors, co-activators (or co-repressors), and adaptors [8].
CITED1 (also known as MSG1) [9] is a well-known adaptor pro-
tein for this complex, and, as such, it acts as a specificity factor
directing the activity of TGF-b-driven transcription. It does so by
binding to SMAD4 and to the non-specific co-activator p300 and
promoting their interaction [10]. CITED1 has been linked to me-
lanocyte pigmentation [9], and it has been shown to play a role
in development [11] and in mediating stemness [12]. CITED1
deregulation is associated with a variety of cancers [9, 11–15].
However, its connection to invasive behavior remains unknown
to date.
Melanoma is the most serious type of skin cancer due to its
high metastatic ability [16]. Skin melanocytes are found in the
basal layer of the epidermis and derive from highly motile neural
crest progenitors [17], which colonize the body during develop-
ment. Neural crest cells undergo EMT early in development,logy 25, 2899–2914, November 16, 2015 ª2015 The Authors 2899
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migrate throughout the embryo, and subsequently differentiate
into a variety of cell types, including melanocytes. The invasive
and metastatic potential of melanoma cells thus reflects their
ability to revert to a less differentiated, neural crest-like pheno-
type [18].
Melanoma cells display an inherent ability to switch between
modes of migration [19, 20]. Among different migratory strate-
gies, rounded-amoeboid behavior is characterized by rounded
morphology as well as blebs as functional protrusions [21], low
levels of adhesion [22, 23], and high levels of actomyosin
contractility, driven by Rho-ROCK [24] and JAK-STAT3 signaling
[25, 26]. Moreover, some types of amoeboid migration have
been reported to be independent of transcriptional regulation
[22, 23]. Rounded-amoeboid behavior is prominent in the inva-
sive fronts of melanomas and breast cancer tumors in animal
models [19, 26, 27] and in human melanoma lesions [25, 26].
The interface between the tumor invasive front and the stroma
favors TGF-b signaling in a paracrine and autocrine manner
[28]. In melanoma, TGF-b-induced genes have been detected
in the invasive fronts of lesions [29].
In the current study, we have explored the role of TGF-
b-dependent transcription in regulating melanoma migratory
strategies using both in vitro and in vivo approaches. We find
that TGF-b, SMAD2, and its adaptor protein CITED1 control
amoeboid migration, independently from the role of TGF-b in
promoting EMT.
RESULTS
TGF-b Promotes Amoeboid Features
To investigate a possible role of TGF-b in controlling cytoskeletal
features in melanoma, we treated different melanoma cell
lines with TGF-b. Interestingly, all melanoma cell lines tested
(SKMEL28, 501MEL, A375P, and WM266.4) increased their
roundness index and their levels of actomyosin contractility
(measured as MLC2 phosphorylation) after treatment with
TGF-b (Figures 1A–1C; Figure S1A).
Since TGF-b is a transcriptional regulator, we analyzed the
transcriptional signature of rounded and highly contractile
A375M2 melanoma cells compared to A375M2 cells treatedFigure 1. TGF-b Promotes Amoeboid Features
(A) Representative confocal images of phospho-MLC2 (pMLC2) immunostaining
TGF-b in serum-free media. F-actin staining is also shown. Scale bar, 20 mm.
(B) Cell morphology (roundness index) of SKMEL28, 501Mel, A375P, andWM266.
independent experiments (n = 3 experiments; n = 100 cells).
(C) Quantification of pMLC2 levels from immunostaining in confocal images from
n = 100). Indicated statistics are versus vehicle.
(D) Gene set enrichment analysis (GSEA) plot of gene expression microarray analy
(H1152, Y27632, blebbistatin). GSEA plot shows the enrichment score on the y axi
ordered on the x axis according to their GSEA enrichment score. Enrichment plots
compared to less contractile cells. Nominal p value <0.001.
(E) Significantly enriched network following network enrichment analysis usingMe
blue circles, and upregulated genes are marked with red circles. Legend ind
categories.
(F) Levels of secreted TGF-b by ELISA in a panel of 16 melanoma cell lines of v
between average roundness index and secreted TGF-b level is also shown.
(G) Cell morphology (roundness index) of A375P cells treated with conditioned me
blocking antibody (n = 3; n = 60). Dots represent single cells from three indepen
n.s., not significant, *p < 0.05, **p < 0.01, ***p < 0.001. Graphs show mean ± SEM
Spearman’s correlation (F). See also Figure S1.
Current Biowith contractility inhibitors (ROCK inhibitors H1152, Y27632,
and blebbistatin, an inhibitor of Myosin II ATPase) or less
contractile A375P cells [26]. Using gene set enrichment analysis
(GSEA), we found a significant enrichment of TGF-b-regulated
genes in rounded and highly contractile cells (Figure 1D).
Furthermore, performing Network Enrichment Analysis with
GeneGo Metacore, we found that in rounded contractile cells
there was a significant enrichment in a network of genes
centered on SMAD signaling (Figures 1E and S1B). Enriched
genes included TGF-bRI, TGF-bRII, SMAD2, SMAD3, and
CITED1.
Since TGF-b itself was not regulated at the mRNA level, we
measured secreted TGF-b by ELISA in a panel of 16 melanoma
cell lines of varying degrees of rounding (Figures 1F and S1C).
Cell morphology in the panel was assessed in cells plated on a
thick layer of collagen I [25, 26]. We found a striking correlation
between roundness and secreted levels of TGF-b (Figure 1F).
As secreted factors work in a concentration-dependent manner,
only cell populations with a roundness index higher than 0.75
secreted enough TGF-b levels to sustain rounding (Figure S1C).
These data could suggest that TGF-b controls amoeboid fea-
tures in an autocrine manner.
In order to understand whether TGF-b can play a role in
controlling cell morphology in a paracrine manner, we treated
low-TGF-b, low-contractility cells (A375P) with conditioned me-
dia from high-TGF-b, high-contractility cells (A375M2). While
A375M2-derived media induced rounding in A375P cells, this
effect was lost in the presence of a TGF-b-neutralizing antibody
(Figures 1G and S1D). These results suggest a possible
paracrine action of TGF-b by regulating amoeboid features in
melanoma.
Downstream of TGF-b, SMAD2 Controls Cytoskeletal
Actomyosin in Melanoma
Downstream of TGF-b, SMADs drive transcriptional programs
important for EMT in carcinomas. SMAD2/3 and SMAD1/5 are
known as R-SMADs and are activated respectively by TGF-b/
Activin/Nodal or BMP signals [31, 32], while SMAD4 acts with
both sets of SMADs [6]. We determined which members of the
SMAD family control the actomyosin cytoskeleton in melanomaof SKMEL28, 501Mel, A375P, and WM266.4 cells upon 24 hr stimulation with
4 cells upon 24 hr stimulation with TGF-b. Dots represent single cells from three
(A). Dots represent single cells from three independent experiments (n = 3;
sis comparing untreated A375M2 cells and contractility-inhibited A375M2 cells
s for genes that are known to be regulated by TGF-b stimulation [30]. Genes are
show upregulation of TGF-b-regulated genes in rounded,more contractile cells
taCore. Following contractility inhibition, downregulated genes aremarkedwith
icates the meaning of the different shapes representing different molecular
arying morphology (n = 3). Cell lines are arranged by morphology; correlation
dia from A375P cells of A375M2 cells with and without the addition of a TGF-b
dent experiments.
. Unpaired t test (B and C); Tukey’s post-test following one-way ANOVA (G);
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Figure 2. Downstream of TGF-b, SMAD2 Controls Cytoskeletal Actomyosin in Melanoma
(A) Representative confocal images of phospho-MLC2 (pMLC2) immunostaining of A375M2 upon SMAD2, SMAD3, SMAD2/3, SMAD4, SMAD1, and SMAD5
knockdown. F-actin staining is also shown. Scale bar, 20 mm. Percentage knockdown by quantitative RT-PCR (qPCR) indicated below the images.
(legend continued on next page)
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by knocking down its members individually via RNAi. Out of all
the SMADs tested (SMAD1, 2, 3, 4, and 5), we observed signifi-
cant loss of roundness (Figures 2A and 2B) and decreased
phospho-MLC2 levels (Figures 2A and 2C) after depletion of
SMAD2, SMAD3, and, to a lesser extent, SMAD4. SMAD2 and
SMAD3 simultaneous depletion did not result in a cumulative ef-
fect and resulted in loss of rounding and reduced contractility
similar to those observed after SMAD2 knockdown alone (Fig-
ures 2A–2C).
We observed the strongest effects after depleting SMAD2,
which resulted in loss of cell rounding, decreased MLC2 activity,
and loss of blebbing (Figures 2A–2D). We verified these results
using two other melanoma cell lines, WM1361 and WM793B
(Figures 2E–2G), and using several oligonucleotides against
SMAD2 (Figures 2H and 2I). These results show that SMAD2 is
required to sustain rounding and actomyosin cytoskeletal activ-
ity in melanoma cells.
Downstream of TGF-b, CITED1 Is Associated with
Contractile Features
CITED1 is an adaptor of the SMAD complex that enhances the
transcription of specific SMAD2/3 target genes [9, 10] down-
stream of TGF-b. We found CITED1 to be downregulated after
actomyosin inhibition (Figure 1E). Moreover, gene set enrich-
ment analysis (GSEA) showed a significant enrichment in
CITED1-regulated genes [33] in rounded and highly contractile
cells (Figure 3A). Accordingly, we found that A375M2 rounded
cells treated with ROCK inhibitors (H1152, Y27632) or compared
with A375P cells not only lost roundness, but also had lower
levels of CITED1 (Figure 3B). Since the functional role of CITED1
in melanoma is unclear, we decided to further investigate its
connection to TGF-b-SMAD2-driven transcription.
CITED1 localization to the nucleus has been associated with
its function [12, 34]. We tested the association between cell
morphology and nuclear CITED1 using the panel of 16 human
melanoma cell lines (Figures 3C and S2A–S2C). Cell morphology
and percentage of nuclear CITED1 using immunofluorescence
were assessed in cells plated on a thick layer of collagen I. The
percentage of nuclear CITED1 significantly correlated with
roundness (Figures 3C and S2A–S2C). We confirmed via
nuclear/cytoplasmic fractionation that rounded cells (A375M2)
have higher levels of nuclear CITED1 than more elongated cells(B) Cell morphology (roundness index) of A375M2 upon SMAD2, SMAD3, SMAD
from three independent experiments (n = 3 experiments; n = 100 cells).
(C) Quantification of pMLC2 levels from immunostaining in confocal images
(n = 3; n = 60).
(D) Percentage of blebbing cells in A375M2 cells on collagen I upon SMAD2 siR
(E) Representative confocal images of pMLC2 immunostaining of WM1361 cell
bar, 20 mm.
(F) Cell morphology (roundness index) of WM1361 and WM793B cells upon SM
pendent experiments (n = 3; n = 30). Percentage knockdown by qPCR is indicat
(G) Quantification of pMLC2 levels from immunostaining in confocal images from
n = 30). Indicated statistics are versus control.
(H) Cell morphology (roundness index) of A375M2 cells upon SMAD2 siRNA knoc
Dots represent individual cells from three independent experiments (n = 3; n = 1
(I) Representative immunoblots (left) and quantification (right) of pMLC2, MLC2, a
(n = 3). Percentage of knockdown by qPCR is shown below.
n.s., not significant, *p < 0.05, **p < 0.01, ***p < 0.001. Graphs show mean ± SEM
(D, F, and G).
Current Bio(A375P) (Figure S2D). Moreover, total CITED1 levels correlated
with roundness using both immunoblotting (IB) and immunofluo-
rescence (IF) techniques (Figures S2E–S2G) (Spearman’s
r = 0.86 using IB and r = 0.9 using IF).
A375M2 cells displayed the highest roundness index [25] and
highest levels of nuclear CITED1 in our cell line panel (Figure 3C).
Therefore, we used A375M2 cells for mouse xenograft studies.
A375M2 cells were injected subcutaneously in nude mice, and
after 4 weeks xenografts were excised and stained for CITED1.
Each sample was scored blindly for staining intensity as nega-
tive (0), low (1), intermediate (2), or high (3). We found a correla-
tion between rounded cell morphology and higher CITED1 levels
in vivo (Figure 3D), both of which correlated with distance from
the core of the tumor (Figure 3E).
We next analyzed CITED1 protein levels in two cohorts of pa-
tient samples using immunohistochemistry (Tables S1 and S2).
As previously described [25, 26], we defined the tumor ‘‘invasive
front’’ as melanoma cells with at least 50% cell surface in
contact with the matrix [25]. We first took into consideration a
cohort of 40 human melanoma patients (‘‘Spanish’’ cohort)
and analyzed melanoma cell roundness and CITED1 staining in-
tensity. Melanoma patients with elongated cells in the tumor
body were less frequent in this cohort (n = 10 patients with elon-
gated cells in the tumor body versus n = 30 patients with
rounded cells in the tumor body) (Figure 3F). However, in the
former we observed significant rounding in the invasive fronts,
which correlated with an increase in CITED1 staining (Figure 3F).
On the other hand, melanomas with rounded cells in the tumor
body displayed significantly higher levels of CITED1 when
compared with tumors with elongated cells in the tumor body
(Figure 3F). Across the whole cohort, we found that CITED1
levels correlated with cell roundness (Figure 3G). We then
analyzed a smaller cohort of melanoma patients (‘‘English’’
cohort) for a more detailed analysis of CITED1 localization. In
these patients, we also observed a correlation between CITED1
staining and cell roundness (Figure 3H). Furthermore, the
average roundness index of the melanoma cells increased in
the invasive fronts, which correlated with percentage of nuclear
CITED1 (Figures 3I and 3J).
These data illustrate howCITED1 is associated with amoeboid
features in melanoma cell lines, in human xenografts, and in mel-
anoma patients.2/3, SMAD4, SMAD1, and SMAD5 knockdown. Dots represent individual cells
from (A). Dots represent individual cells from 3 independent experiments
NA (#1) knockdown (n = 3).
s upon SMAD2 siRNA (#1) knockdown. F-actin staining is also shown. Scale
AD2 siRNA (#1) knockdown. Dots represent individual cells from three inde-
ed below.
(F). Dots represent individual cells from three independent experiments (n = 3;
kdown with SmartPool (#1) and two individual OnTargetplus oligos (#2 and #3).
00).
nd SMAD2 of A375M2 cells on collagen I upon SMAD2 siRNA #1 knockdown
. Tukey’s post-test following one-way ANOVA (B, C, H, and I); unpaired t test
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SMAD2 and CITED1 Work in a Complex that Controls
Amoeboid Behavior
So far, our results indicate a correlation between the expression
of CITED1 and cell rounding. We therefore investigated a
possible functional regulation of cell morphology and actomy-
osin contractility by CITED1 and the SMAD complex.
Similarly to what we observed after SMAD2 knockdown,
CITED1 depletion resulted in reduced cell rounding (Figures 4A
and 4B), decreased MLC2 activity (Figures 4A and 4C), and
loss of blebbing in A375M2 cells (Figure S3A). We verified these
results using WM1361 and WM793B melanoma cell lines (Fig-
ures S3B–S3D) and using several oligonucleotides against
CITED1 (Figures 4A–4C). CITED1 is therefore required to sustain
actomyosin cytoskeletal activity in melanoma cells.
We next established a direct functional link between
SMAD2 and CITED1. CITED1-GFP overexpression resulted in
increased cell rounding (Figures S3E and S3F) and pMLC2
levels (Figures S3E and S3G). However, these effects were
no longer observed if SMAD2 had been depleted from the cells
via RNAi (Figures S3E–S3G). In order to establish the physical
cooperation between these two factors, we performed co-
immunoprecipitation studies. We were able to detect endoge-
nous SMAD2 in immuno-precipitates isolated with HA
antibodies from cells expressing HA-epitope tagged CITED1
(Figure S3H). These results show that SMAD2 and CITED1
work together in a complex to sustain actomyosin contractility
and amoeboid features.
Since SMAD/CITED1 complexes act downstream of TGF-b
signaling, we treated A375P melanoma cells with TGF-b in an
attempt to rescue the induced amoeboid phenotype using
RNAi against CITED1 (Figures 4D–4F). Interestingly, all the
rounded-amoeboid features induced by TGF-b stimulation (Fig-
ure 1), such as rounding, high contractility and blebbing were ab-
lated if CITED1 was depleted (Figures 4D–4F). These resultsFigure 3. Downstream of TGF-b CITED1 Is Associated with Contractile
(A) Gene set enrichment analysis (GSEA) plot of gene expression microarray analy
(H1152, Y27632, blebbistatin) or A375P cells. Enrichment plots show upregulatio
less contractile cells. Nominal p value <0.001.
(B) Representative immunoblot (top) and quantification (bottom) of CITED1 in A37
percentage of rounded cells on top of collagen I is shown below the blot.
(C) Scatterplot of the roundness index and percentage of nuclear CITED1 staining
expression, and horizontal and vertical error bars are ±SEM of x and y variables,
CITED1 (Spearman’s r) is also shown. Data also represented in Figure S2B.
(D) (left) Representative images of different levels of CITED1 immunostaining in mo
typically elongated cell. Scale bar, 20 mm. (right) Quantification of average round
xenografts; n = 700 cells).
(E) (left) Boxplot showing the average roundness cell index in fields taken at incr
levels in fields taken at increasing distance from the center of the xenograft.
(F) (left) Average roundness index and (right) distribution of CITED1 staining for me
predominantly elongated or rounded cell in the tumor body. Patients from the ‘‘Sp
with each category is shown at the bottom. Representative images are shown o
(G) Average roundness index of melanoma cell from samples classified by the
n = 2,860). Representative images of the level of CITED1 staining are shown on
(H) Average roundness index of melanoma cells from samples classified by level o
n = 700). Representative images of the level of CITED1 staining are shown at the
(I) (black axis) Average roundness index of melanoma cells (Pink axis) percentag
primary melanomas. Patients from the ‘‘English’’ cohort of patients (n = 7 patien
(J) Average roundness index of melanoma cells from samples classified by perce
n = 700). Representative images of CITED1 nuclear staining are shown at the bo
n.s., not significant, *p < 0.05, **p < 0.01, ***p < 0.001. Graphs show mean ± SEM
Spearman’s correlation (C), unpaired t test (H), chi-square test (right E and F). Se
Current Biowere similar when using different types of collagen I matrix (Fig-
ure 4E). Of note, the A375P basal levels of rounding/blebbing
and contractility were also reduced after CITED1 depletion, indi-
cating that even low levels of TGF-b signaling still rely on CITED1
to control actomyosin (Figures 4D–4F).
We then investigated whether CITED1was required for TGF-b/
SMAD-driven transcriptional activation in melanoma. We did
so by using a TGF-b/SMAD-dependent reporter construct
(CAGA12-CFP), which measures SMAD-driven transcriptional
activity via CFP expression [2]. We could confirm that A375P
cells respond to TGF-b stimulation, and importantly this tran-
scriptional response was significantly reduced after CITED1
depletion (Figure 4G). These data indicate that CITED1 is an
important link between TGF-b and SMAD-driven transcription
in melanoma.
We next hypothesized that TGF-b could control actomyosin
force in melanoma through SMAD2/CITED1-mediated tran-
scription. This would result in changes in the expression of
genes that can alter actomyosin contractility. After a data-
base/literature search, we selected 24 candidate genes that
have been described as canonical TGF-b targets in different
systems and that could potentially control cytoskeletal actomy-
osin dynamics (see Table S3). We further verified that these
genes were regulated in our microarray (Figure 1D). After stim-
ulation of A375P cells with TGF-b, we measured a significant
increase in the mRNA levels of 17 of the genes tested (Fig-
ure S3I). Importantly, regulation of the expression of half of
these genes (n = 8) was dependent on CITED1 levels (Figures
4H and S3I). These genes could be potential regulators
of contractility downstream of TGF-b/CITED1 transcriptional
activation.
We then individually knocked down these eight genes in
A375P cells and tested the ability of the cells to respond to
TGF-b treatment (Figure 4I). Importantly, depletion of five genesFeatures
sis comparing untreated A375M2 cells and contractility-inhibited A375M2 cells
n of CITED1-regulated genes in rounded, more contractile cells compared to
5M2 upon ROCK inhibition and A375P cells on collagen I. For each condition,
correlation analysis in a panel of 16 melanoma cell lines. Dots represent mean
respectively. Correlation between roundness index and percentage of nuclear
use xenografts of A375M2 cells. Images highlight a typically rounded cell and a
ness index of A375M2 xenografts classified by level of CITED1 staining (n = 5
easing distance from the center of the xenograft. (right) Distribution of CITED1
lanoma cells in the tumor body (T.B.) or the invasive front (I.F.) for samples with
anish’’ cohort (n = 40 patients; n = 2,860 cells). Number of patients associated
n the side. Scale bar, 20 mm.
level of overall CITED1 staining. Patients from the ‘‘Spanish’’ cohort (n = 40;
the side. Scale bar, 20 mm.
f overall CITED1 staining. Patients from the ‘‘English’’ cohort of patients (n = 7;
bottom. Scale bar, 20 mm.
e of cells with CITED1 in the nucleus in the tumor body or the invasive front of
ts; n = 700 cells).
ntage of nuclear CITED1. Patients from the ‘‘English’’ cohort of patients (n = 7;
ttom. Scale bar, 20 mm.
. Tukey’s post-test following one-way ANOVA (B, D, G, I, and J; left E and F),
e also Figure S2.
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Figure 4. SMAD2 and CITED1 Work in a Complex that Controls Amoeboid Behavior
(A) Representative confocal images of phospho-MLC2 (pMLC2) immunostaining of A375M2 cells upon CITED1siRNA SmartPool (#1) knockdown. F-actin is also
shown. Scale bar, 20 mm.
(legend continued on next page)
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(JAK1, LIF, IL11, M-RIP, and ARHGEF5) reduced the ability of
A375P cells to respond to TGF-b stimulation by impairing cell
rounding and increased contractility levels (Figures 4I and 4J).
Furthermore, depletion of JAK1 and LIF led to a significant
decrease in the basal levels of rounding (Figure 4I), in accor-
dance with basal TGF-b activity controlling basal contractile
force. These results indicate that CITED1 acts downstream of
TGF-b, mediating transcriptional control of several genes that
promote rounding (Figure 4I) and actomyosin contractility (Fig-
ure 4J). In particular, this transcriptional regulation involves the
JAK/STAT pathway (JAK1, LIF, and IL11), which is a strong regu-
lator of contractility in melanoma [26]. As expected, loss of
CITED1 resulted in reduced activation of STAT3 signaling,
without affecting SMAD2 phosphorylation levels (Figure S3J).
We also found that the cytoskeletal regulators ARHGEF5 and
M-RIP control TGF-b-dependent contractility in our system
(Figures 4I and 4J). All these data show how TGF-b promotes
actomyosin contractility in melanoma through increasing tran-
scription a set of genes in a CITED1-dependent manner.
TGF-b-SMAD2-CITED1 Control Melanoma Detachment,
Migration, and Invasion
We next recapitulated the steps of melanoma progression
through functional assays to determine whether TGF-b-induced
transcription is functionally relevant in migration and invasion.
Melanoma cells must lose interactions with keratinocytes in
order to invade the dermis. Depletion of SMAD2 or CITED1 in
highly contractile A375M2 cells resulted in higher levels of
attachment to a monolayer of keratinocytes (Figures 5A and
5B). Conversely, addition of TGF-b to less contractile A375P
cells reduced keratinocyte attachment (Figure 5C). TGF-b-treat-
ment also reduced attachment collagen I, while CITED1 and
SMAD2 depletion increased attachment to collagen I (Figures
S4A–S4C). These results are in agreement with amoeboid-con-
tractile migration being less dependent on adhesion to interstitial
collagen I to allow fast migration [27].
Melanoma cells acquire the ability to migrate and invade in the
vertical growth phase, we therefore performed 2D migration and
3D invasion assays. TGF-b stimulation of A375P cells resulted in
increased migration (Figure 5D) and increased 3D invasion using(B) Cell morphology (roundness index) of A375M2 cells upon CITED1 siRNA knoc
(#2, #3). Dots represent individual cells from three independent experiments (n =
(C) Representative immunoblots (left) and quantification (right) of pMLC2, MLC2
(n = 3). Percentage of knockdown by qPCR is shown below.
(D) Representative confocal images of pMLC2 immunostaining of A375P cells on
free media. F-actin is also shown. Scale bar, 20 mm.
(E) (left) Cell morphology (roundness index) of A375P cells upon CITED1 siRNA
staining. Dots represent averages from three independent experiments on atelop
(F) Percentage of blebbing cells in A375P cells upon CITED1 siRNA #1 knockdo
(G) Fold activation of SMAD reporter CAGA12-CFP in A375P cells upon CITED1
(H) Heatmap representing fold decrease in gene expression after CITED1 siRNA #
heatmap. Only genes regulated by both TGF-b andCITED1 are represented. Raw
the right.
(I) Roundness index of A375P cells upon TGF-b treatment and knockdown of LIF,
For each gene, percentage of knockdown by qPCR is shown below graph.
(J) (left) Representative confocal images of phospho-MLC2 (pMLC2) immunostai
F-actin staining is also shown. Scale bar, 20 mm. (right) Quantification of pMLC2
ARHGEF5, and MRIP knockdown. Indicated statistics are versus vehicle unless
n.s., not significant, *p < 0.05, **p < 0.01, ***p < 0.001. Graphs show mean ± SEM
Figure S3.
Current Biodifferent types of collagen I (Figures 5E, S4D, and S4E). How-
ever, depletion of CITED1 or SMAD2 impaired TGF-b-induced
migration and invasion (Figures 5D and 5E), and even basal
levels of invasion were decreased after CITED1 depletion
(Figure 5E). Melanoma cells with intrinsically high levels of
CITED1—such as A375M2—invaded efficiently in a 3D collagen
matrix (Figure 5F) but displayed impaired invasion after pre-
treatment with the TGF-bRI inhibitor SB431542 (Figure 5F) [35].
Conversely, addition of TGF-b to low-contractile A375P cells re-
sulted in increased levels of invasion (Figure 5F). Furthermore,
we observed a decrease in invasion of A375M2 cells if SMAD2
or CITED1 had been silenced (Figure 5G). These results suggest
that TGF-b-dependent transcription controls the ability of mela-
noma cells to escape keratinocyte control, migrate, and invade
through collagen I.
Clinical Relevance of TGF-b-Driven Transcription in
Melanoma Metastasis
In order to understand the clinical significance of the TGF-b tran-
scriptional network in malignant melanoma, we analyzed
expression levels of the SMADs (SMAD1–5) and of the adaptor
CITED1. We also analyzed levels of SMIF, another adaptor
for SMAD-driven transcription [36]. We used publicly available
gene expression data extracted from purified human melanoma
samples derived from the Gene Expression Omnibus (GEO) to
analyze mRNA expression from three independent studies:
Talantov, GEO: GSE3189; Xu, GEO: GDS3966; Kabbarah,
GEO: GDS1989 (Figures 6A and S5A–S5C). We found moder-
ately increased expression of either SMAD2, SMAD3, or
SMAD4 throughout progression (Figure 6A). Interestingly, the
most upregulated gene was the adaptor CITED1 (Figure 6A),
while the other adaptor SMIF was downregulated in some mela-
noma stages (Figure 6A). This suggests that the adaptor CITED1
plays a very specific role in melanoma. Throughout disease pro-
gression, CITED1 levels are strongly increased, while SMAD2/
3/4 levels are only moderately upregulated (Figures S5A–S5C).
This indicates that CITED1 levelsmay be the rate-limiting step di-
recting specific activities of the TGF-b-SMAD transcriptional
complex in melanoma. We next investigated whether CITED1
is associated with survival in melanoma patients using Thekdown with CITED1siRNA SmartPool (#1) and 2 individual OnTargetplus oligos
3; n = 100).
, and CITED1 of A375M2 cells on collagen I upon CITED1 siRNA knockdown
collagen I upon CITED1 siRNA #1 knockdown and TGF-b stimulation in serum-
knockdown and TGF-b stimulation. (right) Quantification of pMLC2 immuno-
eptide collagen I (n = 3; n = 100) and telopeptide intact collagen I (n = 3; n = 60).
wn and TGF-b1 stimulation on atelopeptide collagen I (n = 3).
siRNA #1 knockdown and after TGF-b stimulation (n = 3).
1 knockdown (n = 3) after TGF-b stimulation. Individual repeats are shown in the
data are shown in Figure S3I. Fold decrease after CITED1 depletion is shown on
MYH11, IL11, ARHGAP9, MRIP, MYLPF, ARHGEF5, and JAK1 (n = 3; n = 100).
ning of A375P cells after TGF-b treatment, JAK1 siRNA, and ARHGEF5 siRNA.
immunostaining of A375P cells upon TGF-b stimulation and LIF, JAK1, IL11,
otherwise indicated by horizontal lines.
. Tukey’s post-test following one-way ANOVA (B, C, E–H, U, and J). See also
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Figure 5. TGF-b-SMAD2-CITED1 Control
Melanoma Detachment, Migration, and
Invasion
(A) Representative confocal images of CITED1 #1
and SMAD2 #1 siRNA-transfected A375M2 cells
adhering to a monolayer of keratinocytes dis-
played as a maximum intensity projection. Images
show F-actin staining (red), Hoechst staining
(blue), and A375M2 cells (green, CMFDA staining).
Scale bar, 40 mm.
(B) Percentage of A375M2 cells adhering to a
keratinocyte monolayer upon CITED1 or SMAD2
siRNA #1 knockdown (n = 3).
(C) Percentage of A375P cells adhering to a kera-
tinocyte monolayer. A375P cells were pretreated
with TGF-b for 24 hr before the assay (n = 3).
(D) Migration index for A375P cells after 4 hr of
TGF-b chemotaxis and CITED1 (#1) or SMAD2 (#1)
siRNA knockdown in a transwell chemotaxis assay
(n = 3).
(E) (left) Representative images of A375P cells
invading through collagen I, showing the bottom
of the well (0 mm) and a confocal slice at 50 mm
within the collagen. Scale bar, 50 mm. (right)
Fold change in invasion at 50 mm for A375P cells
after 24 hr of TGF-b stimulation and CITED1 siRNA
(#1) knockdown. Cells invading through atelo-
peptide collagen I (n = 4) or telopeptide intact
collagen I (n = 3).
(F) Invasion index at 50 mm for A375M2 upon
24 hr of SB432564 TGF-bR inhibitor treatment
(left) and A375P cells after 24 hr of TGF-b stimu-
lation (right). Cells invading through atelopeptide
collagen I.
(G) Invasion index at 50 mm for A375M2 cells
invading though atelopeptide collagen I upon
CITED1 or SMAD2 siRNA (#1) knockdown.
n.s., not significant, *p < 0.05, **p < 0.01,
***p < 0.001. Graphs show mean ± SEM. Tukey’s
post-test following one-way ANOVA (B, D, E,
and G), unpaired t test (C and F). See also
Figure S4.Cancer Genome Atlas (TCGA) database (http://cancergenome.
nih.gov/) (n = 354 patients). Interestingly, patients with high
CITED1 expression had a significantly shorter overall survival
than patients with low expression (Figure 6B).
The analysis of gene expression databases suggests that
CITED1 mRNA is highly upregulated in metastasis. We then
confirmed these findings by using IHC in humanmelanoma sam-
ples. In our first cohort of patients (‘‘Spanish’’ cohort), we found
that the average roundness of melanoma cells was increased in
metastatic samples versus primary tumors (Figure 6C). This
observation correlated with an increase in the total levels of
CITED1 in the metastatic lesions compared to the primary tu-
mors (Figure 6D). Furthermore, the percentage of cells with
high levels of nuclear CITED1was increased inmetastatic versus2908 Current Biology 25, 2899–2914, November 16, 2015 ª2015 The Authorsprimary tumors (Figure 6E). Similar results
were observed in our second cohort of
patients (Figures 6F–6H). These observa-
tions indicate that CITED1 is associated
with poor prognosis and that its levelsare higher in metastatic lesions, correlating with amoeboid cyto-
skeletal features in human melanoma patients.
Functional Relevance of TGF-b-CITED1-Driven
Transcription in Melanoma Metastasis In Vivo
As we found that CITED1 highly expressed in metastatic sam-
ples, we confirmed its functional role in supporting melanoma
metastasis. One of the main sites to which melanoma metasta-
sizes is the lung, and high actomyosin contractility in cancer cells
has been reported to promote efficient lung colonization [2, 19,
25]. To test the role of CITED1 downstream of TGF-b-SMAD in
metastatic colonization, we used experimental metastasis as-
says in mice. Tail vein injection is an accepted method to mea-
sure the ability of cancer cells to attach to blood vessels and
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Figure 6. Clinical Relevance of TGF-b-Driven Transcription in Melanoma Metastasis
(A) SMAD1, SMAD2, SMAD3, SMAD4, SMAD5, SMIF, and CITED1 mRNA expression (fold change) using normalized microarray gene expression data from the
indicated studies (N = 277 patients). Raw data are provided in Figures S5A–S5C.
(B) Kaplan-Meier estimates of overall survival in TCGAmelanoma patients according to CITED1 expression. High CITED1 expressionwas significantly associated
with poorer survival in melanoma patients (N = 354; Hazards ratio (HR), 1.81; 95% confidence interval (CI), 1.06–3.09; p = 0.027).
(legend continued on next page)
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survive in the lung [2, 19, 25]. In order to understand how early
the changes in colonization ability could be observed, we
compared TGF-b-treated cells with or without CITED1 in their
ability to colonize the lung. Similar numbers of control or
CITED1-depleted cells lodged in the lung capillaries 30 min after
injection (Figure 7A). However, the number of CITED1-depleted
cells that remained in the lung parenchyma after 6 and 24 hr
was, respectively, 50% and 60% less than the number of control
cells (Figure 7A), showing that CITED1 is important for TGF-
b-mediated colonization in early stages of the process.
Furthermore, TGF-b treatment resulted in increased adhesion
of A375P cells onto endothelial cells (Figure 7B), but this effect
was not sustained if CITED1 had been depleted (Figure 7B).
This suggests that TGF-b/CITED1-driven transcription is
required for melanoma interactions with the vasculature, a
crucial step in extravasation [37]. Importantly, we could confirm
that TGF-b increases lung retention in melanoma 24 hr post tail
vein injection, but these effects were diminished if cells had
been depleted from CITED1 via small interfering RNA (siRNA)
(Figure 7C). These results might be due to increased ability of
melanoma cells to attach to vessels and survive in the lung pa-
renchyma mediated by TGF-b-CITED1 activity. Interestingly,
even in untreated A375P cells with low basal levels of TGF-b
signaling, CITED1 deletion had amarked effect on lung coloniza-
tion (Figure 7C) and melanoma adhesion to endothelia (Fig-
ure 7B). In order to understand whether this early regulation of
lung colonization could eventually lead to successful tumor
outgrowth over time, we generated stable cell lines with reduced
levels of CITED1 using two different small hairpin RNAs (shRNAs)
(Figure 7D). Morphology, contractility, and invasion levels were
decreased in A375P cells depleted of CITED1 when compared
to scramble shRNA (Figures 7D and S6). We analyzed the lungs
20 days after tail vein injection of these cells. Importantly, we
could measure a reduction in the area of the lesions growing in
the lung if cells had reduced levels of CITED1 (Figure 7E). These
results indicate that as a consequence of CITED1 controlling
early events in lung colonization, it is later able to control the abil-
ity of cancer cells to grow at the metastatic site.
DISCUSSION
TGF-b-SMAD-dependent transcription is crucial for EMT [38],
metastatic dissemination, and colonization [2, 39, 40]. Mela-
noma is a highly metastatic cancer that arises frommelanocytes(C) Average roundness index of melanoma cells from patients with primary or m
patients; n = 2,860 cells).
(D) (top) Distribution of CITED1 staining in melanoma cells from patients with pr
patient samples stained for CITED1 (pink) and counterstained with hematoxylin (
patients; n = 2,860 cells).
(E) Percentage of samples classified by level of nuclear localization of CITED1 in
cohort of patients (n = 40; n = 2,860).
(F) Representative images of melanoma patient samples stained for CITED1 (
‘‘English’’ cohort of patients. Scale bar, 20 mm.
(G) Distribution of CITED1 staining intensity in melanoma cells in samples from pa
of patients (n = 7 patients; primary n = 3, metastasis n = 4; n = 700 cells).
(H) Percentage of melanoma cells with nuclear CITED1 in melanoma patient sa
n = 700).
n.s., not significant, *p < 0.05, **p < 0.01, ***p < 0.001. Graphs show mean ± SEM
t test (C and H), chi-square test (D, E, and G). See also Figure S5.
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development [17]. In this study, we investigated how TGF-b
signaling regulates melanoma migration independently of EMT
and how this connects to the actomyosin machinery. Rho-
ROCK signaling in melanoma favors metastatic dissemination
[19, 41, 42], but until now the direct link between the TGF-
b-driven transcription and the Rho-ROCK pathway in cancer
was not understood.
We have found that TGF-b is a potent regulator of the contrac-
tile actomyosin cytoskeleton in melanoma. We show that this
regulation relies on SMAD/CITED1-driven transcription that sus-
tains actomyosin contractility over time (Figure S7). To our
knowledge, this is a novel function of TGF-b signaling, indepen-
dent of its widely studied role in controlling EMT. Neural-crest-
derived malignancies (such as schwanomas, neurofibromas,
and medulloblastomas) [43] might be regulated by TGF-b in a
similar fashion. Moreover, during development TGF-b promotes
neural crest differentiation to highly contractile smooth muscle
cells [44]. It is tempting to speculate that melanocytes retain
this information and acquire the ability to become highly contrac-
tile in response to TGF-b.
On the other hand, the SMAD adaptor CITED1 was originally
described to play a role in melanocyte pigmentation [9]
and has been described to be upregulated in some cancers
[9, 11–15]. CITED1 was shown to be epigenetically regulated
by B-RAFV600E in tumors such as melanoma and thyroid cancer
[15, 45]. In the current study, we used melanoma cell lines
harboring mutations in B-RAF or N-RAS (Table S4), and we
only found a correlation between CITED1 nuclear levels and
actomyosin contractility, independently of genetic background.
CITED1 seems to confer ametastatic advantage by promoting
escape from the primary niche, migration, invasion, attachment
to vessels, successful colonization, and tumor outgrowth. In
particular, CITED1 regulates amoeboid migration and actomy-
osin contractility via a transcriptional program involving several
genes, including JAK1, LIF, IL11, M-RIP, and ARHGEF5. We
do not discard the possibility that other TGF-b target genes
may be involved in the process, but we believewe have identified
a transcriptional program regulated by CITED1 that is sufficient
for sustaining actomyosin contractility over time. Furthermore,
CITED1 mediates TGF-b-driven activation of STAT3, thus
generating a positive feedback loop between TGF-b and
JAK signaling. The role CITED1 plays in driving pro-metastatic
behavior makes it an ideal candidate as a target foretastatic melanoma. Patients from the ‘‘Spanish’’ cohort of patients (n = 40
imary or metastatic melanoma. (bottom) Representative images of melanoma
blue). Scale bar, 20 mm. Patients from the ‘‘Spanish’’ cohort of patients (n = 40
patients with primary or metastatic melanoma. Patients from the ‘‘Spanish’’
pink) and counterstained with hematoxylin staining (blue). Patients from the
tients with primary or metastatic melanoma. Patients from the ‘‘English’’ cohort
mples from (F) and (G). Patients from the ‘‘English’’ cohort of patients (n = 7;
. Tukey’s post-test following one-way ANOVA (A), Kaplan-Meier (B), unpaired
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Figure 7. In Vivo Functional Relevance of TGF-b-Driven Transcription in Melanoma Metastasis
(A) (left) Representative confocal images of mouse lungs 30 min, 6 hr, and 24 hr after tail vein co-injection of A375P cells pretreated with TGF-b (green) and
pretreated with TGF-b and transfectedwith CITED1 siRNA (red). Scale bar, 50 mm. (right) Quantification of the number of retained cell/field in the lung after tail vein
injection. (n = 20 mice). Representative immunoblot for CITED1 shown in the top-right corner.
(B) Percentage of A375P cells adhering to a monolayer of HUVECs after CITED1 siRNA #1 knockdown and upon TGF-b stimulation (n = 3).
(legend continued on next page)
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pharmacological intervention in melanoma. Targeted disruption
of CITED1 activity or ablation of its binding to p300 or SMAD4
could be a good therapeutic opportunity.
The mesenchymal to amoeboid transition has been proposed
to be independent of the activity of transcription factors, relying
upon quick phenotypic adaptations to adjust to changing envi-
ronmental conditions [22, 23]. Nevertheless, in the current study
we propose an intriguing role for TGF-b-driven transcription in
promoting amoeboid dissemination. It will be important to inves-
tigate the role of TGF-b in some developmental programs that
are dependent on amoeboid migration, such as primordial
germ cell migration [46], or immune responses that rely on
lymphocyte amoeboid migration [47]. Since EMT can be stimu-
lated by signals other than TGF-b (such as FGF, PDGF, Wnt,
EGF, and HGF), it will also be necessary to determine whether
these factors can play a role in controlling amoeboid migration.
EXPERIMENTAL PROCEDURES
Cell Culture
WM983A, WM88, WM852, WM3060, WM3854, WM793B, and WM983B were
purchased from the Wistar Collection at Coriell Cell Repository. A375P and
A375M2melanoma cells were fromDr. Richard Hynes (HHMI, MIT). SKMEL28,
501MEL, SKMEL2, WM266.4, SBCL2, WM1361, and WM1366 melanoma
cells were from Professor Richard Marais (Cancer Research UK Manchester
Institute). HaCat cells were from Dr. Ester Martin-Villar (Instituto de Investiga-
ciones Biomedicas). Human umbilical vein endothelial cells (HUVECs) were
from Professor Anne Ridley (King’s College London). Cells were maintained
in DMEM or RPMI and kept in culture for a maximum of three to four passages.
Cell Culture on Thick Layers of Collagen I
Collagen I matrices were prepared using telopeptide intact rat tail collagen
type I (5152A, Advanced Biomatrix at 1.5 mg/ml in DMEM allowed to poly-
merize for 3 hr) or atelopeptide bovine collagen I (5005-B; PureCol, Advanced
BioMatrix at 1.7 mg/ml in DMEM allowed to polymerize for 4 hr). Cells were
imaged after 24 hr in culture in 1% serum media.
RNAi and shRNA Sequences
All siRNA sequences were from Dharmacon. For all genes, siRNA #1 was a
Smartpool (SP) and siRNAs #2 and #3 were On Target (OT) oligos from Dhar-
macon.When only one set of sequences is shown, Smartpool was used. For all
RNAi sequences, see Supplemental Experimental Procedures.
Quantitative Real-Time One-Step PCR
QuantiTect Primer Assays (QIAGEN) and Brilliant III SYBR Green QRT-PCR
1-step system (Agilent Technologies) were used following the manufacturer’s
instructions. GAPDH was used as control.
Immunoblotting
Cells were lysed in Laemmli sample buffer, fractionated in precast 4%–12%
gradient SDS-PAGE (Life Technologies) and transferred to polyvinylidene fluo-
ride (PVDF) filters. The ECL Plus detection Systems (GE Healthcare) with
horseradish peroxidase (HRP)-conjugated secondary antibodies (GE Health-(C) (left) Representative confocal images of mouse lungs 24 hr after tail vein co-inj
without TGF-b pre-treatment. Scale bar, 50 mm. (right) Percentage of retained cel
(n = 24).
(D) Representative confocal images (left) and average roundness index (right) of
collagen I. Scale bar, 20 mm. Dots represent individual cells from three independe
telopeptide intact collagen I of A375P cells stably expressing scramble or CITED
(E) (left) Representative confocal images of A375P cells stably expressing scrambl
bar, 100 mm. (right) Average lesion area for colonies formed in the lung by A375
Percentage of CITED1 knockdown by qPCR is shown below.
n.s., not significant, *p < 0.05, **p < 0.01, ***p < 0.001. Graphs show mean ± SE
2912 Current Biology 25, 2899–2914, November 16, 2015 ª2015 Thecare) were used for detection. Western blot bands were quantified using
ImageJ (http://rsb.info.nih.gov/ij/). For a list of antibodies, see Supplemental
Experimental Procedures.
Animal Welfare
All animals were maintained under specific pathogen-free conditions and
handled in accordance with the Institutional Committees on Animal Welfare
of the UK Home Office (The Home Office Animals Scientific Procedures Act,
1986). All animal experiments were approved by the Ethical Review Process
Committee at King’s College London and carried out under license from the
Home Office, UK.
Human Sample Collection and Patient Information
Patients were staged and classified according to the American Joint Commit-
tee on Cancer Melanoma Staging and Classification criteria [48]. Human
samples were collected with informed written consent, in accordance with
the Helsinki Declaration, and the study design was approved by the Guy’s
Research Ethics Committee and Ethics Committee of Guy’s and St Thomas’
NHS Foundation Trust and the Ethics Committee of the IRBLleida Biobanc,
in accordance with the Human Tissue Act, 2004. Tables S1 and S2 show clin-
ical information from human melanoma patients.
Immunohistochemistry
Slides were dewaxed, treated for antigen retrieval, and incubated with CITED1
antibody. Antibody detection was performed using alkaline phosphatase-con-
jugated secondary antibodies and developed with Dako Liquid Permanent
Red Chromogen (K0640, Dako). The tumor invasive front was defined as the
region of the tumor composed by only melanoma cells with at least 50% cell
surface in contact with the matrix [26]. For details on quantification, see Sup-
plemental Experimental Procedures.
Statistical Analysis
For survival analysis, TCGA expression data were categorized using a Z score
cutoff of 1.0. Survival curves were estimated by the Kaplan-Meier method us-
ing the log-rank test. The hazard ratio (HR) was calculated using the Cox pro-
portional hazard model. Survival analysis was performed using SPSS (IBM).
Data were plotted as a minimum-to-maximum boxplot and superimposed
with dots representing single cells. Other statistical tests were performed
using GraphPad Prism (GraphPad); see end of each figure legend for details.
Chi-square tests were performed to compare CITED1 staining levels: when
comparing elongated-core with rounded-core tumors, the data for the invasive
front and the tumor core were grouped together before performing the test.
Error bars indicate ±SEM.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, four tables, and Supple-
mental Experimental Procedures and can be found with this article online at
http://dx.doi.org/10.1016/j.cub.2015.09.054.
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